Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years’ discoveries and developments

Fig. 5

Study progress of stathmin and MicroRNAs. a Over-expression of miR-31 restores chemo-response by reducing stathmin expression; miR-101/stathmin pathway contributes to radioresistance in human NPC; down-regulation of miR-193b promotes migration and proliferation of tumor cells by targets stathmin; miR-223 regulates stathmin by JNK signaling pathway to regulate MPM cell motility; b up-regulation of miR193b reduces proliferation and migration by inhibiting stathmin and uPA; silencing of miR-210 promotes proliferation of cancerous cells; transfection of miR-142 and miR-223 decreases expression of stathmin and IGF-1R to inhibit proliferation of cancerous cells; c microrna-9 inhibits cell proliferation, vasculogenic mimicry and tumor growth through controlling stathmin expression; miR-101 suppresses autophagy via targets stathmin and down-regulation of miR-101 is linked to the increase of cellular proliferation and invasiveness. miRNAs small non-coding regulatory RNAs, JNK c-JunN-terminalkinase, uPA urokinase-type plasminogen activator, IGF-1R insulin-like growth factor-1 receptor, MPM malignant pleural mesothelioma

Back to article page